Abstract Details

Title Assessing Thrombectomy Capacity and Characteristics of Thrombectomy Capable Centers World-wide Using the MT2020+ Global Thrombectomy Tracking Smartphone App ?

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-005

Background Since 2015, mechanical thrombectomy(MT) has been established as the first-line therapy for large vessel occlusion; however, MT remains underutilized globally, which is driven, in part, by income-based disparities in MT access. The Society of Vascular and Interventional Neurology (SVIN) Mission Thrombectomy 2020+(MT2020+) is a global alliance and campaign that aims to reduce this disparity and democratize MT access for patients globally utilizing public health interventions. A novel smartphone application, GTT App, was designed to characterize thrombectomy centers globally and quantitate MT cases in near real-time geo-tagged to the thrombectomy centers.

Objective To deploy a survey through the Global Thrombectomy Tracking(GTT) App to understand MT capacity and characteristics of thrombectomy centers worldwide.

Design/Methods The GTT-APP was launched in November 2019 to promote the mission of MT2020+. A voluntary 10-question survey was deployed through the GTT-App to gain insight into local systems-of-care. The survey questions pertained to the population density, organizational structure, academic affiliation, available imaging modalities, t-PA usage, and case volumes. Users of the GTT-App, primarily neuro-interventionalists, were prompted to complete the survey when logged into the GTT-App.

Results

Of the 338-users from 16-countries over 19-months, 49 neuro-interventionalists participated in the survey on the GTT App. Majority(71.5%) are practicing in large metropolis with population >1 million, of which 16.3% are in mega-cities with >10 million. The centers are government-funded(46.9%), private(40.8%) or charitable (12.2%). Most stroke centers are academic hospitals (81.6%)and 55.1% have neurointerventional trainees. At most centers(87.7%) IV-tPA is available with annual treatment rate between >5% for 55.1%. Most centers(57.1%) utilize additional CTP scans prior to MT. For 69.3% respondents, the annual MT case volume is between 10-100 cases.

Conclusions Our survey shows that the GTT APP can generate important Thrombectomy-capacity and characteristics data at regional-levels on a global-scale, which can be used for targeted funding and resource allocation to accelerate access to MT.

Authors/Disclosures
Syed F. Zaidi, MD (ProMedica Stroke Network) PRESENTER	Dr. Zaidi has nothing to disclose.
	No disclosure on file
Kaiz S. Asif, MD (Ascension Health)	Dr. Asif has nothing to disclose.
Santiago Ortega Gutierrez, MD (University of Iowa)	Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for stryker. Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for medtronic. Dr. Ortega Gutierrez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for microvention. Dr. Ortega Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Ortega Gutierrez has received research support from stryker. The institution of Dr. Ortega Gutierrez has received research support from Medtronic. The institution of Dr. Ortega Gutierrez has received research support from Methinks. The institution of Dr. Ortega Gutierrez has received research support from NIH.
Violiza A. Inoa, MD	No disclosure on file
Nabeel Herial, MD, MPH, FAAN (N/A)	Dr. Herial has nothing to disclose.
Fawaz Al-Mufti, MD (Westchester Medical Center at New York Medical College)	Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Revalesio .
Viktor Szeder, MD, PhD	Dr. Szeder has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Szeder has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Carroll, Kelly, Trotter, Franzen, McBride & Peabody LLP. Dr. Szeder has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Peabody and Buccini LLP.
Dileep R. Yavagal, MD, FAAN (University of Miami Miller School of Medicine)	Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line.